Showing results (2071-2080 of 2,571) with videos related to

Sort By:
Pageof 258
Intestinal Research|August 12, 2024
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international studyAntonio Tursi, Daniele Piovani, Giovanni Brandimarte, et al.
The European Physical Journal. C, Particles and Fields|February 25, 2022
Punzi-loss:: a non-differentiable metric approximation for sensitivity optimisation in the search for new particlesF Abudinén, M Bertemes, S Bilokin, et al.
La Radiologia Medica|December 1, 1979
[Multi-institution, multidisciplinary radiology and endoscopy trial of the diagnostic accuracy of the double contrast examination of the stomach surface]P Aguzzi, F Andreoli, C Bartolozzi, et al.
United European Gastroenterology Journal|August 8, 2023
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysisAntonio Tursi, Daniele Piovani, Giovanni Brandimarte, et al.
Inflammatory Bowel Diseases|May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
American Journal of Medical Genetics. Part A|July 29, 2022
Identifying phenotypic expansions for congenital diaphragmatic hernia plus (CDH+) using DECIPHER dataAmy Hardcastle, Aliska M Berry, Ian M Campbell, et al.
Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Infectious Diseases and Therapy|July 12, 2024
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort StudyDaniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, et al.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Pageof 258